16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome

Guilherme R. de Jesús; Ashley E. Benson; Cecilia B. Chighizola; Savino Sciascia; David W. Branch

doi:10.1177/0961203320954520

16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome

Guilherme R. de Jesús, Ashley E. Benson, Cecilia B. Chighizola, Savino Sciascia, David W. Branch

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Obstetric antiphospholipid syndrome (APS) remains a clinical challenge for practitioners, with several controversial points that have not been answered so far. This Obstetric APS Task Force met on the 16th International Congress on Antiphospholipid Antibodies in Manchester, England, to discuss about treatment, diagnostic and clinical aspects of the disease. This report will address evidence-based medicine related to obstetric APS, including limitations on our current management, the relationship between antibodies against domain 1 of β2GPI and obstetric morbidity, hydroxychloroquine use in patients with obstetric APS and factors associated with thrombosis after obstetric APS. Finally, future directions for better understanding this complex condition are also reported by the Task Force coordinators.

Original language	English (US)
Pages (from-to)	1601-1615
Number of pages	15
Journal	Lupus
Volume	29
Issue number	12
DOIs	https://doi.org/10.1177/0961203320954520
State	Published - Oct 1 2020
Externally published	Yes

Keywords

Antiphospholipid syndrome
anti-β2GPI domain 1 antibodies
antiphospholipid antibodies
hydroxychloroquine
thrombosis

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1177/0961203320954520

Cite this

@article{9a59f3160b234d7396ac8b366fe1440f,

title = "16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome",

abstract = "Obstetric antiphospholipid syndrome (APS) remains a clinical challenge for practitioners, with several controversial points that have not been answered so far. This Obstetric APS Task Force met on the 16th International Congress on Antiphospholipid Antibodies in Manchester, England, to discuss about treatment, diagnostic and clinical aspects of the disease. This report will address evidence-based medicine related to obstetric APS, including limitations on our current management, the relationship between antibodies against domain 1 of β2GPI and obstetric morbidity, hydroxychloroquine use in patients with obstetric APS and factors associated with thrombosis after obstetric APS. Finally, future directions for better understanding this complex condition are also reported by the Task Force coordinators.",

keywords = "Antiphospholipid syndrome, anti-β2GPI domain 1 antibodies, antiphospholipid antibodies, hydroxychloroquine, thrombosis",

author = "{de Jes{\'u}s}, {Guilherme R.} and Benson, {Ashley E.} and Chighizola, {Cecilia B.} and Savino Sciascia and Branch, {David W.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2020.",

year = "2020",

month = oct,

day = "1",

doi = "10.1177/0961203320954520",

language = "English (US)",

volume = "29",

pages = "1601--1615",

journal = "Lupus",

issn = "0961-2033",

publisher = "SAGE Publications Ltd",

number = "12",

}

TY - JOUR

T1 - 16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome

AU - de Jesús, Guilherme R.

AU - Benson, Ashley E.

AU - Chighizola, Cecilia B.

AU - Sciascia, Savino

AU - Branch, David W.

N1 - Publisher Copyright: © The Author(s) 2020.

PY - 2020/10/1

Y1 - 2020/10/1

N2 - Obstetric antiphospholipid syndrome (APS) remains a clinical challenge for practitioners, with several controversial points that have not been answered so far. This Obstetric APS Task Force met on the 16th International Congress on Antiphospholipid Antibodies in Manchester, England, to discuss about treatment, diagnostic and clinical aspects of the disease. This report will address evidence-based medicine related to obstetric APS, including limitations on our current management, the relationship between antibodies against domain 1 of β2GPI and obstetric morbidity, hydroxychloroquine use in patients with obstetric APS and factors associated with thrombosis after obstetric APS. Finally, future directions for better understanding this complex condition are also reported by the Task Force coordinators.

AB - Obstetric antiphospholipid syndrome (APS) remains a clinical challenge for practitioners, with several controversial points that have not been answered so far. This Obstetric APS Task Force met on the 16th International Congress on Antiphospholipid Antibodies in Manchester, England, to discuss about treatment, diagnostic and clinical aspects of the disease. This report will address evidence-based medicine related to obstetric APS, including limitations on our current management, the relationship between antibodies against domain 1 of β2GPI and obstetric morbidity, hydroxychloroquine use in patients with obstetric APS and factors associated with thrombosis after obstetric APS. Finally, future directions for better understanding this complex condition are also reported by the Task Force coordinators.

KW - Antiphospholipid syndrome

KW - anti-β2GPI domain 1 antibodies

KW - antiphospholipid antibodies

KW - hydroxychloroquine

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85090248441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090248441&partnerID=8YFLogxK

U2 - 10.1177/0961203320954520

DO - 10.1177/0961203320954520

M3 - Article

C2 - 32883160

AN - SCOPUS:85090248441

SN - 0961-2033

VL - 29

SP - 1601

EP - 1615

JO - Lupus

JF - Lupus

IS - 12

ER -

16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this